1-20 of 50
Fei Fei
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Free
Sairah Ahmed, Avyakta Kallam, Matthew Frigault, Bradley D. Hunter, Sagar S. Patel, David Bernasconi, Soyoung Kim, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Marcelo C. Pasquini, Jennifer L. Crombie
Journal: Blood
Blood (2024) 144 (Supplement 1): 472.
https://doi.org/10.1182/blood-2024-199702
Published: 2024
Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Free
Maria Silvina Odstrcil Bobillo, Swetha Kambhampati, Dasom Lee, Bradley D. Hunter, Ogechukwu Egini, Krish Patel, Patrick M. Reagan, David Bernasconi, Soyoung Kim, Charimar Santiago Parrilla, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Sairah Ahmed, Jennifer L. Crombie, Saurabh Dahiya, Mehdi Hamadani, Catherine J. Lee, Marcelo C. Pasquini, Mazyar Shadman, Alex F. Herrera, Matthew Frigault
Journal: Blood
Blood (2024) 144 (Supplement 1): 470.
https://doi.org/10.1182/blood-2024-199723
Published: 2024
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Free
Jeremy S. Abramson, Manali Kamdar, Fei Fei Liu, Alessandro Crotta, Alessandro Previtali, Sven L. Klijn, Pearl Wang, Yixie Zhang, Ashley Bonner, Matthew Lunning
Journal: Blood
Blood (2024) 144 (Supplement 1): 3130.
https://doi.org/10.1182/blood-2024-200937
Published: 2024
Journal Articles

Double-Hit/Triple-Hit Myeloma: An Adverse Prognostic Factor That Can be Overcome By Minimal Residual Disease Negativity

Free
Yang Yang, Wenjing Wang, Liang Ren, Yawen Wang, Aziguli Maihemaiti, Tianwei Lan, Chi Zhou, Panpan Li, Pu Wang, Jing Li, Jiadai Xu, Tianhong Xu, Fei-fei Chen, Peng Liu
Journal: Blood
Blood (2024) 144 (Supplement 1): 6956.
https://doi.org/10.1182/blood-2024-207788
Published: 2024
Journal Articles

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Free
Jennifer L. Crombie, Loretta J. Nastoupil, Charalambos Andreadis, Iris Isufi, Bradley Hunter, Allison Winter, Brian Hess, Stefan K. Barta, Michael J. Frigault, Maria Lia Palomba, Natalie S. Grover, Michael D. Jain, Tamara K. Moyo, Sagar S. Patel, Priyanka A Pophali, David Bernasconi, Charimar Santiago Parrilla, Amani Kitali, Fei Fei Liu, Mecide Gharibo, Marcelo Pasquini
Journal: Blood
Blood (2023) 142 (Supplement 1): 104.
https://doi.org/10.1182/blood-2023-180242
Published: 2023
Journal Articles

Clinical Characterization of Hepatic Light Chain Amyloidosis in the Chinese Population: A Single-Center Retrospective Analysis

Free
Chen Chen, Chenqi Yu, Jing Li, Weiguang Wang, Zhimei Wang, Lu-Ya Cheng, Fei-fei Chen, Jiadai Xu, Tianhong Xu, Yang Yang, Wenjing Wang, Pu Wang, Peng Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6745.
https://doi.org/10.1182/blood-2023-186600
Published: 2023
Journal Articles

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Free
Pere Barba, Sally Lanar, Fei Fei Liu, Laurie Eliason, Kshawna Askew, Jennifer Devlen, Ulrika Furustrand, Ana Kostic
Journal: Blood
Blood (2023) 142 (Supplement 1): 7352.
https://doi.org/10.1182/blood-2023-178858
Published: 2023
Journal Articles

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

Free
Ming-Yue Fei, Yong Wang, Bin-He Chang, Kai Xue, Fangyi Dong, Dan Huang, Xi-Ya Li, Zi-Juan Li, Cheng-Long Hu, Ping Liu, Ji-Chuan Wu, Peng-Cheng Yu, Ming-Hua Hong, Shu-Bei Chen, Chun-Hui Xu, Bing-Yi Chen, Yi-Lun Jiang, Na Liu, Chong Zhao, Jia-Cheng Jin, Dan Hou, Xin-Chi Chen, Yi-Yi Ren, Chu-Han Deng, Jia-Ying Zhang, Li-juan Zong, Rou-Jia Wang, Fei-Fei Gao, Hui Liu, Qun-Ling Zhang, Ling-Yun Wu, Jinsong Yan, Shuhong Shen, Chun-Kang Chang, Xiao-Jian Sun, Lan Wang
Journal: Blood
Blood (2023) 142 (10): 903–917.
https://doi.org/10.1182/blood.2022019537
Published: 2023
Includes: Supplemental data
Journal Articles

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Free
Yuliya Linhares, Fei Fei Liu, Cesar Freytes, Mohamad Cherry, Ling Shi, Weiqin Liao, Julia Braverman, Ricardo Espinola, Min Vedal, Bassam Mattar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10930–10931.
https://doi.org/10.1182/blood-2022-159645
Published: 2022
Journal Articles

Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Free
Fei Fei Liu, Krishnaveni Subbiah, Tao Gu, Trong Kim Le
Journal: Blood
Blood (2022) 140 (Supplement 1): 2414–2415.
https://doi.org/10.1182/blood-2022-162587
Published: 2022
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Free
Jeremy S. Abramson, Manali Kamdar, Fei Fei Liu, Alessandro Crotta, Alessandro Previtali, Sven L. Klijn, Pearl Wang, Aaron Situ, Yixie Zhang, Ashley Bonner, Matthew A. Lunning
Journal: Blood
Blood (2022) 140 (Supplement 1): 4655–4656.
https://doi.org/10.1182/blood-2022-160216
Published: 2022
Journal Articles

Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

Free
Nilanjan Ghosh, Alison R. Sehgal, Fei Fei Liu, Ana Kostic, Alessandro Crotta, Lily Peng, Marc De Benedetti, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 10430–10431.
https://doi.org/10.1182/blood-2022-159686
Published: 2022
Journal Articles

An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study

Free
Clinical Trials & Observations
Si-Qi Li, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Meng Lv, Fei-Fei Tang, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu, Ying-Jun Chang, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (5): 516–520.
https://doi.org/10.1182/blood.2021014604
Published: 2022
Includes: Supplemental data
Journal Articles

Prevalence and Risk Factors of Antibodies to Class I and II Human Leukocyte Antigens in Haploidentical Allograft Candidates: A Prospective Study on 3805 Subjects

Free
Ning Ma, Lan-Ping Xu, Xiaohui Zhang, Yu Wang, Huan Chen, Wei Han, Yuqian Sun, Chenhua Yan, Fei-Fei Tang, Xiaodong Mo, Yan-Rong Liu, Kaiyan Liu, Xiao Jun Huang, Ying-Jun Chang
Journal: Blood
Blood (2021) 138 (Supplement 1): 2880.
https://doi.org/10.1182/blood-2021-149088
Published: 2021
Journal Articles

Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Free
Christopher Parker, Fei Fei Liu, Kristen Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J Keating, Sonja Sorensen, Emily Dorman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3003.
https://doi.org/10.1182/blood-2021-150755
Published: 2021
Journal Articles

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Results from the Phase 3 Transform Study

Free
Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Fei Fei Liu, Julia Braverman, Shien Guo, Ling Shi, Manali Kamdar
Journal: Blood
Blood (2021) 138 (Supplement 1): 3845.
https://doi.org/10.1182/blood-2021-151611
Published: 2021
Journal Articles

Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Free
Tanya Siddiqi, Ulrich Jaeger, Olga Moshkovich, Julia Braverman, Fei Fei Liu, Sally Lanar, Matthew Miera, Selam Shah, Jennifer Devlen, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4098.
https://doi.org/10.1182/blood-2021-151823
Published: 2021
Journal Articles

Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience

Free
Wen-Jing Yu, Jinsong JIA, Jing Wang, Fei-Fei Tang, Lizhong Gong, Xiaohong Liu, Xiaolu Zhu, Xiaosu Zhao, Xiao Jun Huang, Hao Jiang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4413.
https://doi.org/10.1182/blood-2021-148259
Published: 2021
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Free
David G. Maloney, MD PhD, John Kuruvilla, MD, Christopher P Fox, MD PhD, Guillaume Cartron, MD PhD, Daniel Li, PhD, Jens Hasskarl, MD, Ashley Bonner, PhD, Yixie Zhang, PhD, Fei Fei Liu, BSc, MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-137719
Published: 2020
Journal Articles

Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Free
Tanya Siddiqi, MD, Ulrich Jaeger, MD, Olga Moshkovich, MPH, Jennifer Devlen, PhD, Matthew Miera, BSc, Agnes Williams, MSc, Jens Hasskarl, MD, Fei Fei Liu, BSc, MBA, Julia Braverman, PhD, Gilles Salles, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-137656
Published: 2020